Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

N Bourne, FJ Bravo, M Francotte… - The Journal of …, 2003 - academic.oup.com
N Bourne, FJ Bravo, M Francotte, DI Bernstein, MG Myers, M Slaoui, LR Stanberry
The Journal of infectious diseases, 2003academic.oup.com
In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2
glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (Al) and 3-deactylated
monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection
against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and
limited protection against infection (46% in study 1 and 39% in study 2). In the present
report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 …
Abstract
In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection
Oxford University Press